Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Br J Radiol Retrieve available abstracts of 43 articles: HTML format

Single Articles

December 2022
1. SHU X, Liu Y, Qiao X, Ai G, et al
   Radiomic-Based machine learning model for the accurate prediction of prostate cancer risk stratification.
   Br J Radiol. 2022 Dec 7:20220238. doi: 10.1259/bjr.20220238.
   PubMed     Abstract available
   
   
   July 2022
2. LIU Y, Wang S, Xiang LH, Xu G, et al
   The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
   Br J Radiol. 2022 Jul 25:20220209. doi: 10.1259/bjr.20220209.
   PubMed     Abstract available
   
   
   May 2022
3. MORI N, Mugikura S, Takase K
   The role of magnetic resonance imaging in prostate cancer patients on active surveillance.
   Br J Radiol. 2022 May 23:20220140. doi: 10.1259/bjr.20220140.
   PubMed    
   
   
   March 2022
4. BUSCH JJ JR
   The role for MRI-guided transurethral ultrasound ablation in the continuum of prostate cancer care.
   Br J Radiol. 2022;95:20210959.
   PubMed     Abstract available
   
   
   
5. FUTTERER JJ, Kim CK, Margolis DJ
   Innovations in prostate cancer: introductory editorial.
   Br J Radiol. 2022;95:20229003.
   PubMed    
   
   
   
6. WANG L, Margolis DJ, Chen M, Zhao X, et al
   Quality in MR reporting (include improvements in acquisition using AI).
   Br J Radiol. 2022;95:20210816.
   PubMed     Abstract available
   
   
   
7. GAUDIANO C, Rustici A, Corcioni B, Ciccarese F, et al
   PI-RADS version 2.1 for the evaluation of transition zone lesions: a practical guide for radiologists.
   Br J Radiol. 2022;95:20210916.
   PubMed     Abstract available
   
   
   
8. LEE CH, Vellayappan B, Tan CH
   Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.
   Br J Radiol. 2022;95:20210509.
   PubMed     Abstract available
   
   
   February 2022
9. KARANASIOS E, Caglic I, Zawaideh JP, Barrett T, et al
   Prostate MRI quality: clinical impact of the PI-QUAL score in prostate cancer diagnostic work-up.
   Br J Radiol. 2022 Feb 18:20211372. doi: 10.1259/bjr.20211372.
   PubMed     Abstract available
   
   
   January 2022
10. SRITHARAN K, Tree A
    MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.
    Br J Radiol. 2022 Jan 24:20210800. doi: 10.1259/bjr.20210800.
    PubMed     Abstract available
    
    
    December 2021
11. ASLAM S, Tsang J, Bickle I, Saiepour A, et al
    Multi-parametric MRI prostate PIRAD scoring in a district general hospital: Correlating PIRADS 3 results with histological findings.
    Br J Radiol. 2021 Dec 17:20210804. doi: 10.1259/bjr.20210804.
    PubMed     Abstract available
    
    
    
12. GARMER M, Karpienski J, Groenemeyer DH, Wagener B, et al
    Structured reporting in radiologic education - Potential of different PI-RADS versions in prostate MRI controlled by in-bore MR-guided biopsies.
    Br J Radiol. 2021 Dec 16:20210458. doi: 10.1259/bjr.20210458.
    PubMed     Abstract available
    
    
    
13. TURKBEY B, Haider MA
    Deep learning-based artificial intelligence applications in prostate MRI: brief summary.
    Br J Radiol. 2021 Dec 3:20210563. doi: 10.1259/bjr.20210563.
    PubMed     Abstract available
    
    
    November 2021
14. COLE AP, Langbein BJ, Giganti F, Fennessy FM, et al
    Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer.
    Br J Radiol. 2021 Nov 26:20210840. doi: 10.1259/bjr.20210840.
    PubMed     Abstract available
    
    
    
15. CHO HH, Kim CK, Park H
    Overview of radiomics in prostate imaging and future directions.
    Br J Radiol. 2021 Nov 19. doi: 10.1259/bjr.20210539.
    PubMed     Abstract available
    
    
    
16. LIU FY, Sheng TW, Tseng JR, Yu KJ, et al
    Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET/CT vs PET/MRI.
    Br J Radiol. 2021 Nov 12:20210728. doi: 10.1259/bjr.20210728.
    PubMed     Abstract available
    
    
    
17. GIROMETTI R, Giannarini G, Panebianco V, Maresca S, et al
    Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
    Br J Radiol. 2021 Nov 11:20210886. doi: 10.1259/bjr.20210886.
    PubMed     Abstract available
    
    
    
18. DIAS AB, O'Brien C, Correas JM, Ghai S, et al
    Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review.
    Br J Radiol. 2021 Nov 9:20210633. doi: 10.1259/bjr.20210633.
    PubMed     Abstract available
    
    
    
19. VAN LUIJTELAAR A, Futterer JJ, Bomers JG
    Minimally invasive magnetic resonance image-guided prostate interventions.
    Br J Radiol. 2021 Nov 1:20210698. doi: 10.1259/bjr.20210698.
    PubMed     Abstract available
    
    
    October 2021
20. DEL MONTE M, Cipollari S, Del Giudice F, Pecoraro M, et al
    MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques.
    Br J Radiol. 2021 Oct 5:20210528. doi: 10.1259/bjr.20210528.
    PubMed     Abstract available
    
    
    September 2021
21. DESAI S, Costa DN
    PI-RADS and Likert scales for structured reporting in multiparametric MR imaging of the prostate.
    Br J Radiol. 2021 Sep 29:20210758. doi: 10.1259/bjr.20210758.
    PubMed     Abstract available
    
    
    
22. WU YY, Fan KH
    Proton therapy for prostate cancer: current state and future perspectives.
    Br J Radiol. 2021 Sep 24:20210670. doi: 10.1259/bjr.20210670.
    PubMed     Abstract available
    
    
    
23. TAMADA T, Kido A, Ueda Y, Takeuchi M, et al
    Clinical impact of ultra-high b-value (3000 s/mm(2)) diffusion-weighted magnetic resonance imaging in prostate cancer at 3T: comparison with b-value of 2000 s/mm(2).
    Br J Radiol. 2021 Sep 24:20210465. doi: 10.1259/bjr.20210465.
    PubMed     Abstract available
    
    
    
24. UENO Y, Tamada T, Sofue K, Murakami T, et al
    Diffusion and quantification of diffusion of prostate cancer.
    Br J Radiol. 2021 Sep 19:20210653. doi: 10.1259/bjr.20210653.
    PubMed     Abstract available
    
    
    
25. SUSHENTSEV N, Caglic I, Rundo L, Kozlov V, et al
    Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression.
    Br J Radiol. 2021 Sep 19:20210842. doi: 10.1259/bjr.20210842.
    PubMed     Abstract available
    
    
    
26. ZAPATERO A, Roch M, Castro Tejero P, Buchser D, et al
    MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
    Br J Radiol. 2021 Sep 19:20210683. doi: 10.1259/bjr.20210683.
    PubMed     Abstract available
    
    
    August 2021
27. LEE YS, Choi MH, Lee YJ, Han D, et al
    Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.
    Br J Radiol. 2021 Aug 20:20210479. doi: 10.1259/bjr.20210479.
    PubMed     Abstract available
    
    
    
28. IPPOLITI S, Fletcher P, Orecchia L, Miano R, et al
    Optimal biopsy approach for detection of clinically significant prostate cancer.
    Br J Radiol. 2021 Aug 6:20210413. doi: 10.1259/bjr.20210413.
    PubMed     Abstract available
    
    
    
29. CHAPET O, Udrescu C, Bin S, Decullier E, et al
    Prostate hypofractionated radiotherapy (62Gy at 3.1Gy per fraction) with injection of hyaluronic acid: final results of the RPAH1 study.
    Br J Radiol. 2021;94:20210242.
    PubMed     Abstract available
    
    
    July 2021
30. PAXTON M, Barbalat E, Perlis N, Menezes RJ, et al
    Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer.
    Br J Radiol. 2021 Jul 29:20210414. doi: 10.1259/bjr.20210414.
    PubMed     Abstract available
    
    
    
31. JAGER A, Vilanova JC, Michi M, Wijkstra H, et al
    The challenge of prostate biopsy guidance in the era of mpMRI detected lesion: ultrasound-guided versus in-bore biopsy.
    Br J Radiol. 2021 Jul 29:20210363. doi: 10.1259/bjr.20210363.
    PubMed     Abstract available
    
    
    
32. ZHANG L, Jiang D, Chen C, Yang X, et al
    Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer.
    Br J Radiol. 2021 Jul 21:20210191. doi: 10.1259/bjr.20210191.
    PubMed     Abstract available
    
    
    
33. BENHMIDA S, Beneux A, Udrescu C, Rouviere O, et al
    Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.
    Br J Radiol. 2021 Jul 20:20210142. doi: 10.1259/bjr.20210142.
    PubMed     Abstract available
    
    
    
34. MAZZOLA R, Sicignano G, Cuccia F, Vitale C, et al
    Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.
    Br J Radiol. 2021 Jul 20:20210521. doi: 10.1259/bjr.20210521.
    PubMed     Abstract available
    
    
    
35. KIM Y, Park JJ, Kim CK
    Blood oxygenation level-dependent MRI at 3T for differentiating prostate cancer from benign tissue: a preliminary experience.
    Br J Radiol. 2021 Jul 8:20210461. doi: 10.1259/bjr.20210461.
    PubMed     Abstract available
    
    
    
36. GIGANTI F, Allen C, Stavrinides V, Stabile A, et al
    Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?
    Br J Radiol. 2021 Jul 8:20210321. doi: 10.1259/bjr.20210321.
    PubMed     Abstract available
    
    
    
37. GIGANTI F, Kasivisvanathan V, Kirkham A, Punwani S, et al
    Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score.
    Br J Radiol. 2021 Jul 8:20210415. doi: 10.1259/bjr.20210415.
    PubMed     Abstract available
    
    
    June 2021
38. KUMASAKA S, Motegi S, Kumasaka Y, Nishikata T, et al
    Whole-body magnetic resonance imaging (WB-MRI) with diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) in prostate cancer: Prevalence and clinical significance of incidental findings.
    Br J Radiol. 2021 Jun 11:20210459. doi: 10.1259/bjr.20210459.
    PubMed     Abstract available
    
    
    
39. QUINTERO P, Cheng Y, Benoit D, Moore C, et al
    Effect of treatment planning system parameters on beam modulation complexity for treatment plans with single-layer multi-leaf collimator and dual-layer stacked multi-leaf collimator.
    Br J Radiol. 2021;94:20201011.
    PubMed     Abstract available
    
    
    April 2021
40. BROOKS RL, McCallum HM, Pearson RA, Pilling K, et al
    Are cone beam CT image matching skills transferrable from planning CT to planning MRI for MR-only prostate radiotherapy?
    Br J Radiol. 2021 Apr 29:20210146. doi: 10.1259/bjr.20210146.
    PubMed     Abstract available
    
    
    
41. URASE Y, Ueno Y, Tamada T, Sofue K, et al
    Comparison of prostate imaging reporting and data system v2.1 and 2 in transition and peripheral zones: evaluation of interreader agreement and diagnostic performance in detecting clinically significant prostate cancer.
    Br J Radiol. 2021 Apr 21:20201434. doi: 10.1259/bjr.20201434.
    PubMed     Abstract available
    
    
    
42. KUO YH, Liang JA, Chen GH, Li CC, et al
    Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis.
    Br J Radiol. 2021 Apr 16:20200456. doi: 10.1259/bjr.20200456.
    PubMed     Abstract available
    
    
    March 2021
43. HE X, Xiong H, Zhang H, Liu X, et al
    Value of MRI texture analysis for predicting new Gleason grade group.
    Br J Radiol. 2021 Mar 11:20210005. doi: 10.1259/bjr.20210005.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: